Foundayo became the first approved nonpeptide small-molecule GLP-1 obesity drug in 2026, replacing injectable peptide chemistry with a tablet that can be taken without food or water restrictions.
Endogenex, Inc. reported on July 8 that enrollment has been completed in its pivotal ReCET clinical study, a prospective, randomized, double-blinded and sham-controlled trial evaluating an investigational endoscopic procedure in adults with inadequately controlled type 2 diabetes. The study enrolled 350 participants across approximately 40 sites in the United States and Australia under a U.S.
Endogenex has completed enrollment in the ReCET Clinical Study, a pivotal evaluation of the Endogenex System in adults with type 2 diabetes whose blood glucose levels remain inadequately controlled on non-insulin glucose-lowering medications. The study has enrolled 350 patients across approximately 40 sites in the United States and Australia, moving the clinical-stage medical device developer
Find out how Insulet’s Omnipod 6 and fully closed-loop data could reshape automated insulin delivery for diabetes care.
Find out how Dexcom G7 data could reshape CGM adoption for type 2 diabetes patients not using insulin.
Read how Corcept’s ADA data could reshape hypercortisolism screening in difficult-to-control type 2 diabetes and GLP-1 care.
Cirius Therapeutics is pushing CIR-0602K into the ADA 2026 spotlight. Find out why insulin sensitivity may be diabetes’ next battleground.
Genentech advances enicepatide and petrelintide obesity data at ADA 2026. Find out why Roche’s strategy matters now.
ClearNote Health will present Avantect pancreatic cancer test validation data at ASCO 2026. Find out what it could mean for early detection.
Generic semaglutide is cheaper, but access is now the real battleground. Phoenix and Raven are testing Canada’s GLP-1 telehealth future.